Syndax Pharmaceuticals, Inc. Short-Term Debt
Syndax Pharmaceuticals, Inc. (SNDX) had Short-Term Debt of $344.03 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:DebtCurrent · last filed 2026-08-04
- 2026-06-30: Debt, Current $344.03M.
- 2026-03-31: Debt, Current $343.96M.
- 2025-12-31: Debt, Current $343.91M.
- 2025-09-30: Debt, Current $343.91M.
| Period end | Debt, Current |
|---|---|
| 2026-06-30 | $344.03M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $343.96M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $343.91M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $343.91M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $343.85M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $343.79M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $343.68M 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |